How to measure (or not) compliance to eradication therapy
Ana Paula MARTINS1,2, Ana Patrícia FERREIRA3, Filipa Alves da COSTA1,4, José CABRITA5
- 1PhD; Centre for Pharmacoepidemiological Research (CEFAR-ANF), .
- 2PhD; Faculty of Pharmacy, University of Lisbon, Portugal.
- 3MSc; Centre for Pharmacoepidemiological Research (CEFAR-ANF), .
- 4PhD; Instituto Superior de Ciências da Saúde Egas Moniz, Lisbon, Portugal.
- 5PhD, Professor of Social Pharmacy; Faculty of Pharmacy, University of Lisbon, Portugal.
Volume 4, Issue 2 · pp. 88–94 · PUBLISHED 2026 · DOI:
ABSTRACT
This study aimed to test a novel method of compliance measurement in Portuguese community pharmacy in Helicobacter pylori patients. A case series design was used where compliance indicators were electronically measured, aside with patients’ reports. Experienced adverse drug reactions, perceived benefit of therapy and quality of life were also measured. Mean compliance proportion was 56% and a positive impact on patients’ perceived health status was found. The method used was welcomed by community pharmacists, albeit having an influence on patients’ normal behaviour.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
MARTINS, A. P., FERREIRA, A. P., COSTA, F. A. D., & CABRITA, J. (2026). How to measure (or not) compliance to eradication therapy. Pharmacy Practice, 4(2), 88–94.